Completed PHASE2 INTERVENTIONAL 2-arm NCT00923936

Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

Sponsor: National Cancer Institute (NCI)

Interventions Bevacizumab Liposomal Doxorubicin

Updated 8 times since 2017 Last updated: Jun 26, 2018 Started: Apr 23, 2009 Primary completion: May 13, 2015 Completion: Nov 8, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00923936, this PHASE2 trial focuses on Sarcoma, Kaposi and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE2

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2017 — Jul 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States